Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 942-582-7 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute oral toxicity:
Read-across from three source analogues Potassium sulfate (CAS 7778-80-5), Sodium sulfate (CAS 7757-82-6) and Calcium sulfate (CAS 7778-18-9): The three substances are not considered to be hazardous for acute oral toxicity in the rat (Product Safety Laboratories, 2000; Harlan Laboratories LTD, 2010; NIER, 2003). Based on the analogy approach applied, the target substance is not considered to be hazardous for acute oral toxicity according to CLP (LD50 > 2000 mg/kg bw is attributed).
Acute dermal toxicity:
Dermal LD50 (rat) > 2000 mg/kg bw with no mortality and no systemic clinical signs (Reliability 1 key study; GLP compliant; OECD 402 test guideline) (CiToxLAB Hungary Ltd., 2017)
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- other: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: read-across data
- Remarks:
- original study is of reliability 2 (a limited documented study according to test guidelines and GLP).
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 425 (Acute Oral Toxicity: Up-and-Down Procedure)
- GLP compliance:
- yes
- Test type:
- up-and-down procedure
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- According to test guidelines, no further information
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- Prior to use, the test substance was ground in a coffee mill and administered by gavage as a 60% w/w suspension in distilled water (preliminary solubility testing indicated that suspensions in excess of 60% were too viscous to be administered properly).
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 3
- Control animals:
- not specified
- Details on study design:
- An initial dose of two thousand milligrams of the test substance per kilogram of bodyweight was administered to one healthy female rat by oral gavage. Due to the absence of mortality in this animal a second female received the same dose level. Following the completion of dosing and 100% survival in a total of three females, a group of three males was tested (simultaneously) at the above dose level. All animals were observed for mortality, signs of gross toxicity, and behavioral changes at least once daily for 14 days after dosing. Bodyweights were recorded prior to administration and again on Days 7 and 14 (termination) after dosing. Necropsies were performed on all animals at terminal sacrifice.
- Statistics:
- no data
- Preliminary study:
- not relevant
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Mortality:
- All animals survived.
- Clinical signs:
- other: All animals appeared active and healthy throughout the study period.
- Gross pathology:
- No signs of toxicity were observed.
- Other findings:
- no
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Potassium magnesium sulphate is considered not harmful for acute oral toxicity.
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Peer reviewed secondary data source.
- Guideline:
- other: not mentioned
- GLP compliance:
- not specified
- Test type:
- other: acute oral toxicity
- Species:
- rat
- Strain:
- not specified
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- no data
- Route of administration:
- oral: unspecified
- Vehicle:
- not specified
- Details on oral exposure:
- no data
- Details on study design:
- no data
- Key result
- Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- 6 600 mg/kg bw
- Interpretation of results:
- other: not specified
- Conclusions:
- LD50 (rat) for Potassium sulfate = 6600 mg/kg bw
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 18-Feb-2010 to 11-Mar-2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- This study has been performed in compliance with the Swiss Ordinance relating to Good Laboratory Practice, adopted May 18th, 2005 [SR 813.112.1]. This Ordinance is based on the OECD Principles of Good Laboratory Practice, as revised in 1997 and adopted November 26th, 1997 by decision of the OECD Council [C(97)186/Final].
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories B.V., Kreuzelweg 53, 5961 NM Horst / The Netherlands
- Age when treated: 10 weeks
- Body Weight when treated: 170.3 g – 187.4 g
Housing: In groups of three in Makrolon type-4 cages with wire mesh tops and standard softwood bedding (‘Lignocel’ J. Rettenmaier&Söhne GmbH&CoKG, 73494 Rosenberg / Germany, imported by Provimi Kliba AG, 4303 Kaiseraugst / Switzerland).
- Diet: Pelleted standard Provimi Kliba 3433 rat/mouse maintenance diet, batch no. 60/09 (Provimi Kliba AG, 4303 Kaiseraugst / Switzerland) ad libitum (except for the overnight fasting period prior to intubation and approximately 3-4 hours post dose).
Water: Community tap water from Füllinsdorf ad libitum.
-Acclimatization period: 18-Feb-2010 to 22-Feb-2010 (the first three females), 18-Feb-2010 to 24-Feb-2010 (the remaining three females)
ENVIRONMENTAL CONDITIONS
- Temperature: 22 ± 3 °C
- Humidity: between 30 - 70%
- Air changes: 10 - 15 air changes per hour
- Photperiod: 12 hours light and 12 hours dark
IN-LIFE DATES: 23-Feb-2010 to 11-Mar-2010 - Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Remarks:
- (PEG 300)
- Details on oral exposure:
- The animals received a single dose of the test item by oral gavage administration at 2000 mg/kg body weight after being fasted for approximately 17 to 20 hours (access to water was permitted). Food was provided again approximately 3 hours after dosing.
TEST MATERIAL
Dose levels were in terms of the test item as supplied by the Sponsor.
The dose formulations were prepared shortly before each dosing occasion using a magnetic stirrer, a spatula and an Ultra-Turrax as homogenizers.
The dosing volume was 10 mL/kg body weight. - Doses:
- 2000 mg/kg at a dose volume of 10 mL/kg
- No. of animals per sex per dose:
- 3 females
- Control animals:
- no
- Details on study design:
- Threee females were first treated.Since no relevant clinical signs were observed and no death occurred 48 hours after test item administration, the test was completed using the three remaining females.
- Duration of observation period following adminsitration: 15 days
- Frequency of observation period following administration: within the first 30 minutes and at approximately 1, 2, 3 and 5 hours after administration on test day 1. Once daily during days 2-15.
- Necropsy of survivors performed: yes
- Other examinations performed: viability/ Mortality, clinical signs, body weights - Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Mortality:
- All animals survived until the end of the study period with the exception of one animal, which spontaneously died shortly after administration due to application in wrong way.
- Clinical signs:
- other: Slight sedation was observed in two animals from 1 to 2 hours after administration and persisted as moderate in one animal up to the 5-hour reading. Hunched posture was also noted in the two animals at the 2-hour reading and persisted in one animal up to
- Gross pathology:
- Dark red lungs congested, in which contained dark red hemorrhagic-watery fluid, were noted at necropsy in the animal which died spontaneously due to a technical failure.
The remaining animals were devoid of any macroscopic findings at the scheduled necropsy. - Interpretation of results:
- GHS criteria not met
- Conclusions:
- The median lethal dose of Sodium Sulphate after single oral administration to female rats, observed over a period of 14 days, is:
LD50 (female rat): greater than 2000 mg/kg body weight - Executive summary:
Two groups, each consisting of three female RccHan:WIST (SPF) rats, were treated with Sodium Sulphate by single oral gavage administration at a dosage of 2000 mg/kg body weight. The test item was formulated in PEG300 at a concentration of 0.2 g/mL and administered at a dosing volume of 10 mL/kg.
The animals were examined daily during the acclimatization period and mortality, viability and clinical signs were recorded. All animals were examined for clinical signs within the first 30 minutes and approximately 1, 2, 3 and 5 hours after treatment on day 1 and once daily during test days 2-15. Mortality/viability was recorded within the first 30 minutes and approximately 1, 2, 3 and 5 hours after administration on test day 1 (with the clinical signs) and twice daily during days 2-15. Body weights were recorded on day 1 (prior to administration) and on days 8 and 15.All animals were necropsied and examined macroscopically.
All animals survived until the end of the study period with the exception of one animal, which spontaneously died shortly after administration due to a technical failure.
Clinical signs, including sedation, hunched posture and ruffled fur, were noted in two animals on test day 1 and were distributed from the 1- to the 5-hour post-dose. Both animals were devoid of any clinical signs from test day 2 to the end of the study. No clinical signs were observed in the surviving females throughout the observation period.
The body weight of the animals was within the range commonly recorded for this strain and age.
Dark red congested lungs, with dark red hemorrhagic-watery fluid, were noted at necropsy of the animal which died spontaneously immediately after gavage. These findings clearly suggested technical failure during the gavage procedure.
The median lethal dose of Sodium Sulphate after single oral administration to female rats, observed over a period of 14 days, is:
LD50 (female rat): greater than 2000 mg/kg body weight
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
- GLP compliance:
- yes
- Test type:
- fixed dose procedure
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 9 ~ 11 weeks
- Weight at study initiation: 194.9 ~ 206.6 g (sighting study), 194.9 ~ 203.6 g (main study)
- Fasting period before study: Animals were fasted the night before administration but fodder was offered 3 to 4 hours after the administration
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- DOSAGE PREPARATION: Test substance was dissolved in the distilled water on the day of administration
- Rationale for the selection of the starting dose: In order to determine the appropriate starting dose for the main test, 50, 300 and 2,000 mg/kg of test substance were administered to each animal in a sighting study, but there were no toxic effects at least 2 days after the administration. - Doses:
- 50, 300 and 2000 mg/kg b.w
- No. of animals per sex per dose:
- In the screening study one female rat was used in each of the three doses. In the main test a further 4 female rats were administered with 2000 mg/kg of the test material.
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Mortality, clinical signs and toxic effects were observed 0.5, 1, 2, 3 and 4 hours after the treatment on the day of administration, after that were observed at least once a day till necropsy. Body weight was measured on day 1, 7 and 14.
- Necropsy of survivors performed: yes - Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 1 581 mg/kg bw
- Remarks on result:
- other: The LD50 for calcium sulfate dihydrate was > 2000 mg/kg bw. The value has been calculated for calcium sulfate anhydrous
- Mortality:
- No mortality was observed within every dose level
- Clinical signs:
- other: There were no specific clinical signs during test period
- Gross pathology:
- No abnormal necropsy opinions in relation to administration of calcium sulfate, dihydrate.
- Interpretation of results:
- GHS criteria not met
- Remarks:
- The hydrated form exhibited no signs of toxicity whatsoever at the highest, dose therefore even with a correction to the anhydrous form which is lower that the limit dose, the anhydrous form is also considered not classified.
- Conclusions:
- The study was performed with calcium sulfate dihydrate which gave an LD 50 >2000 mg/kg. Based on this result the oral LD50 of calcium sulfate anydrous is >1581 mg/kg b.w
- Endpoint:
- acute toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: read across from reliability 1 or 2 studies
- Justification for type of information:
- See attached document.
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Species:
- rat
- Key result
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Based on read-across data from three source analogues Potassium sulfate (CAS 7778-80-5), Sodium sulfate (CAS 7757-82-6) and Calcium sulfate (CAS 7778-18-9) (all three analogues are not considered to be hazardous for acute oral toxicity in the rat), the target substance is not considered to be hazardous for acute oral toxicity according to CLP (LD50 > 2000 mg/kg bw is attributed).
Referenceopen allclose all
Table 1: Mortality of Females (Group Summary)
Dose (mg/kg) |
No. Dead/No. Dosed |
Number of Deaths |
|||||||||||||
Days After Dosing |
|||||||||||||||
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
||
50 |
0/1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
300 |
0/1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2000 |
0/5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Table 2: Incidence of Clinical Signs in Females (Group Summary)
Signs observed |
Dose level mg/kg |
50 |
300 |
2000 |
Appears normals |
|
1/1* |
1/1 |
5/5 |
*: No. of animals with the sign/No. of animals examined |
Table 3: Body Weights of Females (group summary)
Dose (mg/kg) |
Animal Number |
|
||||
Day 0 |
Day 1 |
Day 7 |
Day 14 |
Gain |
||
50 |
1 |
194.9 |
214.0 |
234.2 |
243.0 |
48.1 |
300 |
2 |
200.2 |
225.6 |
229.6 |
235.2 |
35.0 |
2000 |
3 |
206.6 |
224.6 |
235.2 |
247.6 |
41.0 |
4 |
194.9 |
214.6 |
222.4 |
227.8 |
32.9 |
|
5 |
201.8 |
220.8 |
232.0 |
236.2 |
34.4 |
|
6 |
203.6 |
217.6 |
220.0 |
224.8 |
21.2 |
|
7 |
198.4 |
217.8 |
219.4 |
234.2 |
35.8 |
|
Mean |
201.1 |
219.1 |
225.8 |
234.1 |
33.1 |
|
SD |
4.55 |
3.79 |
7.30 |
8.84 |
7.30 |
|
N |
5 |
5 |
5 |
5 |
5 |
Table 4: Gross Findings of Females (Group Summary)
Dose (mg/kg) |
Gross Observation |
Frequency |
||
Location |
Observation |
Mortalities |
Survivors |
|
0 |
No gross findings |
|
0/0* |
1/1 |
300 |
No gross findings |
|
0/0 |
1/1 |
2000 |
No gross findings |
|
0/0 |
5/5 |
* No. of animals with the sign/No. of animals examined |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- GLP compliant read across studies performed according to current guidelines
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 7 April 2017 to 2 June 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- yes
- Remarks:
- Relative humidity value (28%) outside the expected range of 30-70% was recorded at one time. This deviation was considered to have no impact on the outcome of the study.
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: EXP LIberica Lote Al16503047
- Expiration date of the lot/batch: 30 November 2019
- Purity test date: 1 February 2017
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Controlled room temperature (15-25 deg Celsius, below 70% relative humidity) protected from light and humidity
- Stability under test conditions: not applicable
- Solubility and stability of the test substance in the solvent/vehicle: not applicable
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
The test item was ground to a fine powder before the application. Sufficient water was used to dampen the test material to ensure good contact with the skin. - Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Germany
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: Young adult rats
- Weight at study initiation: Between 219 g and 266 g
- Fasting period before study: No
- Housing: Type II. polypropylene/polycarbonate
- Diet (e.g. ad libitum): ssniff® SM R/M "Autoclavable complete diet for rats and mice breeding and maintenance", ad libitum
- Water (e.g. ad libitum): tap water from the municipal supply, as for human consumption from a 500 mL bottle, ad libitum
- Acclimation period: 5 Days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20.4–24.7°C
- Humidity (%): 28–61%
- Air changes (per hr): 15-20 air exchanges/hour
- Photoperiod (hrs dark / hrs light): 12 hours daily, from 6.00 a.m. to 6.00 p.m.
IN-LIFE DATES: From: 6 April 2017 To: 25 April 2017 - Type of coverage:
- semiocclusive
- Vehicle:
- water
- Details on dermal exposure:
- TEST SITE
- Area of exposure: back of the animals
- % coverage: approximately 10% area of the total body surface
- Type of wrap if used: Sterile gauze pads maintened with adhesive hypoallergenic plaster.The entire trunk was wrapped with semi occlusive plastic wrap for 24 hours
REMOVAL OF TEST SUBSTANCE
- Washing (if done): washing with water at body temperature
- Time after start of exposure: 24 hours
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg bw
- Concentration (if solution): not applicable
- Constant volume or concentration used: adjusted to animal bodyweight
- For solids, paste formed: yes - Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 5 animals per sex per dose were used
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Clinical observations were performed on the day of treatment at 1 and 5 hours after application of the test item and once each day for 14 days thereafter. Observations included the skin and fur, eyes and mucous membranes, the respiratory, circulatory, autonomic and central nervous system, somatomotor activity and behaviour pattern. Particular attention was directed to observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma. The body weights were recorded on Day 0 (before the test item administration) and on Days 7 and 14 (before necropsy). Adverse skin reactions at the site of application were recorded daily following the removal of the dressing.
- Necropsy of survivors performed: yes - Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- The test item did not cause mortality at the dose level of 2000 mg/kg bw.
- Clinical signs:
- other: There were no systemic clinical signs noted in any animal throughout the study
- Gross pathology:
- There was no evidence of any gross macroscopic changes at a dose level of 2000 mg/kg bw.
- Other findings:
- No adverse local dermal signs were observed after treatment with the test item or during the 14 days observation period.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute dermal median lethal dose (LD50) of the test item Sulfates of potassium, sodium and calcium, by-product from fermentation was found to be greater than 2000 mg/kg body weight in male and female Crl:WI rats. According to the CLP criteria, the test item was not classified for Acute Dermal Hazard.
- Executive summary:
The purpose of this GLP compliant study was to assess the potential Acute Toxicity of the test substance Sulfates of potassium, sodium and calcium, by-product from fermentation, when applied dermally on Wistar rats, perfomed according to OECD 402 method.
A limit test was carried out at 2000 mg/kg body weight (bw) in both sexes (5 rats/sex). The test item was powdered and was applied as a single dermal 24- hour exposure followed by a 14-day observation period.
Clinical observations were performed on all animals at 1 and 5 hours after dosing and daily for 14 days thereafter. Body weight was measured prior to dosing on Day 0 and on Days 7 and 14 (before necropsy). Gross macroscopic examination was performed on all animals at the end of the 2-week observation period (Day 14).
Test item did not cause mortality at the dose level of 2000 mg/kg bw.
There were no systemic clinical signs noted in any animal throughout the study.
No adverse local dermal signs were observed after treatment with the test item or during the 14 days observation period.
There were no treatment related effects on body weight or body weight gain during the observation period.
There was no evidence of any macroscopic changes at a dose level of 2000 mg/kg bw.
The acute dermal median lethal dose (LD50) of the test item Sulfates of potassium, sodium and calcium, by-product from fermentation was found to be greater than 2000 mg/kg body weight in male and female Crl:WI rats. According to the CLP criteria, the test item was not classified for Acute Dermal Hazard.
Reference
TABLE 1: Clinical Observations
DOSE LEVEL: 2000mg/kg bw SEX:MALE
Cage No. |
Animal No. |
Observations |
Observation days |
Frequency |
|||||||||||||||
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||||
1h |
5h |
||||||||||||||||||
1 |
7970 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
2 |
7971 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
3 |
7972 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
4 |
7973 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
5 |
7974 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
DOSE LEVEL: 2000mg/kg bw SEX:FEMALE
Cage No. |
Animal No. |
Observations |
Observation days |
Frequency |
|||||||||||||||
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||||
1h |
5h |
||||||||||||||||||
6 |
7985 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
7 |
7986 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
8 |
7987 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
9 |
7988 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
10 |
7989 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
Remarks: += present
h =hour(s) Treatment day = Day0
Frequency of observation = number of occurence of observation / total number of observations
TABLE 2: Body Weight Data
DOSE LEVEL: 2000mg/kgbw SEX:MALE
Cage No. |
Animal No. |
Body weight (g) Days |
Body Weight Gain (g) |
||||
0 |
7 |
14 |
0-7 |
7-14 |
0-14 |
||
1 |
7970 |
253 |
310 |
369 |
57 |
59 |
116 |
2 |
7971 |
238 |
272 |
307 |
34 |
35 |
69 |
3 |
7972 |
242 |
305 |
361 |
63 |
56 |
119 |
4 |
7973 |
241 |
285 |
339 |
44 |
54 |
98 |
5 |
7974 |
234 |
273 |
313 |
39 |
40 |
79 |
Mean: |
241.6 |
289.0 |
337.8 |
47.4 |
48.8 |
96.2 |
|
Standard deviation: |
7.1 |
17.7 |
27.7 |
12.2 |
10.6 |
22.1 |
DOSE LEVEL: 2000mg/kgbw SEX:FEMALE
Cage No. |
Animal No. |
Body weight (g) Days |
Body Weight Gain (g) |
||||
0 |
7 |
14 |
0-7 |
7-14 |
0-14 |
||
6 |
7985 |
264 |
276 |
298 |
12 |
22 |
34 |
7 |
7986 |
266 |
272 |
277 |
6 |
5 |
11 |
8 |
7987 |
256 |
270 |
279 |
14 |
9 |
23 |
9 |
7988 |
234 |
238 |
246 |
4 |
8 |
12 |
10 |
7989 |
219 |
257 |
260 |
38 |
3 |
41 |
Mean: |
247.8 |
262.6 |
272.0 |
14.8 |
9.4 |
24.2 |
|
Standard deviation: |
20.5 |
15.5 |
19.8 |
13.6 |
7.4 |
13.3 |
TABLE 3: Macroscopic Findings
DOSE LEVEL: 2000mg/kgbw SEX:MALE
Cage No. |
Animal No. |
Necropsy Date/ Necropsy Day |
External Observations |
Internal Observations |
Organ/ Tissue |
1 |
7970 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
2 |
7971 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
3 |
7972 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
4 |
7973 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
5 |
7974 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
DOSE LEVEL: 2000mg/kgbw SEX:FEMALE
Cage No. |
Animal No. |
Necropsy Date/ Necropsy Day |
External Observations |
Internal Observations |
Organ/ Tissue |
6 |
7985 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
7 |
7986 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
8 |
7987 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
9 |
7988 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
10 |
7989 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- GLP compliant study performed according to OECD guideline 402 (reliability 1)
Additional information
Acute toxicity: oral
No acute oral toxicity data is available for the substance Sulfates of potassium sodium and calcium, by-product from fermentation. However, data are available on the three sulfate salts: Sodium sulfate (CAS 7757-82-6), Potassium sulfate (CAS 7778-80-5) and Calcium Sulfate (CAS7778-18-9) and a read across approach was used to fulfill data requirement for this endpoint.
The read across approach is based on the results of the transformation/dissolution study performed on the registered substance (Envigo Research Limited, 2016). This study demonstrated that Sulfates of potassium sodium and calcium, by-product from fermentation is completely transformed/dissolved (98.1%) within 30 minutes at pH 2 and at 37 °C. Hence, upon systemic uptake into the body, the registered substance will be present in dissolved form as sulfate anions and potassium, sodium and calcium cations. Furthermore, the three salts Sodium sulfate, Potassium sulfate and Calcium Sulfate are also completely dissociated in aqueous media in Sulfate anions and the respective cations, then this justifies that toxicity data can be read across from the three salts Sulfates of potassium, Sulfates of sodium and Sulfates of calcium to the target substance for systemic toxicity endpoints.
A read across key study (OECD TG 420; NIER, 2003) is available for Calcium Sulfate (CAS 7778-18-9). Calcium sulfate dihydrate (CAS 10101-41-4) was administered to rats by gavage at 2000 mg/kg bw. No mortality and no systemic clinical signs were observed, so the oral LD50 for rats was > 2000 mg/kg bw. Based on this result, the calculated oral LD50 of Calcium sulfate anhydrous (CAS 7778-18-9) is >1581 mg/kg b.w. A key study (OECD 423; Harlan Laboratories LTD, 2010) is available for Sodium sulfate (CAS 7757-82-6). Rats were given the test item at 2000 mg/kg bw by oral gavage. The LD50 value was greater than 2000 mg/kg bw based on the absence of mortality or treatment related clinical signs. A read across key study (OECD TG 425; Product Safety Laboratories, 2000) is available for Potassium Sulfate (CAS 7778-80-5). Potassium magnesium sulphate (CAS 17855-14-0) was administered to rats by gavage at 2000 mg/kg bw. No mortality and no systemic clinical signs were observed, so the oral LD50 for rats was > 2000 mg/kg bw. Additionally, a reliability 4 supporting data (Secondary data sources) is also available on the Potassium Sulfate substance itself (International Uniform Chemical Information Database, 2000; Hazardous Substances Data Bank (HSDB), 1999; RTECS, 1999). An LD50 (rat) of 6600 mg/kg bw was found for Potassium Sulfate (i.e. > 2000 mg/kg bw).
The results of the above acute oral toxicity studies are indicative of a similar low toxicity for the three analogue substances. Hence, based on these data and on the analogy approach, Sulfates of potassium, sodium and calcium, by-product from fermentation is not considered to be hazardous for acute oral toxicity (acute oral LD50 greater than 2000 mg/kg bw is attributed).
Acute toxicity: dermal
One GLP compliant study (OECD 402, Citoxlab, 2017) is available for evaluation of the Sulfates of potassium, sodium and calcium, by-product from fermentation, in which rats were treated with 2000 mg/kg bw of the substance by dermal route. The LD50 value was stated to be higher than this value due to absence of mortality.
Reliable experimental data for acute dermal toxicity is also available for the analogue Potassium sulfate (CAS 7778-80-5) (OECD 402, NOTOX B.V. 2010). Rats were exposed dermally to 2000 mg/kg bw for 24 hours. No mortality, body weight change abnormalities or gross pathology abnormalities were observed. Chromodacryorrhoea was noted in two males and one female on Day 1 and scales and scabs were noted in one male and one female between Day 5 and 11. Hence the LD50 value was determined to be greater than 2000 mg/kg bw. The very similar behavior of this analogue substance with the target substance for acute dermal effects further reinforces the read across justification applied for the systemic toxicity endpoints.
Acute toxicity: inhalation
Waiving for exposure considerations and scientifically unjustified
Justification: No data are available to evaluate the acute inhalation toxicity. According to column 2 part 8.5.2 of Annex VIII of REACh, the choice for the second route will depend on the nature of the substance and the likely route of human exposure. "Testing by the inhalation route is appropriate if exposure of humans via inhalation is likely, taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size". The test substance at room temperature is a solid made up of single crystalline particles. The melting point is > 400°C and thus, the vapor pressure determination does not need to be conducted (melting point is > 300°C). Based on these data, Sulfates of potassium sodium and calcium, by-product from fermentation is considered to have a low volatility potential. The substance has a Mass Median Aerodynamic Diameter (MMAD) of 378.181 µM with only 10 % of the test material particle size < 144.244 µM. According to Guidance on Information Requirements and Chemical Safety Assessment Chapter R.7a: Endpoint specific guidance (Version 6.0; July 2017), particles larger than 100 μM are less likely to be inhalable. Based on the overall physicochemical data, no exposure by inhalation is expected. Furthermore, the dermal route is the likely route of human exposure. According to the available dermal acute toxicity data, as well as the acute oral toxicity read across data, no toxic effects are expected and no test is required for the acute inhalation toxicity endpoint.
Justification for classification or non-classification
Acute Toxicity, oral: While no acute oral information is available for the target substance, all three read-across substances have acute oral LD50 values greater than 2000 mg/kg bw (in the rat). Based on the read-across rationale and the weight of evidence, the substance does not meet the criteria for classification according to Regulation (EC) No 1272/2008.
Acute Toxicity, dermal: reliable (GLP compliant; OECD Test Guideline 402) acute dermal toxicity data is available for the target substance. The results showed an acute dermal LD50 value greater than 2000 mg/kg bw in the rat (no mortality and no clinical signs). Based on this key study, the substance does not meet the criteria for classification according to Regulation (EC) No 1272/2008.
Acute Toxicity, inhalation: see waiving rationale in "Justification for type of information"
Specific Target Organ Toxicity– Single Exposure: Based on the data available on both the target substance and the read-across substances, the target substance is not likely to exhibit significant toxic effects arising from a single exposure. As a result, the substance does not meet the criteria for classification according to Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.